NCT05771402View on ClinicalTrials.gov

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Hepatitis bAnti-PD-1 AntibodyPeg-IFNα
Interventions
DRUG

Anti-PD-1 antibody

Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection

DRUG

NAs

Once/day, 1 capsule/time, oral

DRUG

Peg-IFNα

Once/week, 180μg/time, subcutaneous injection

Trial Locations (1)

400010

RECRUITING

The 2nd affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
collaborator

The Affiliated Hospital Of Southwest Medical University

OTHER

collaborator

Guizhou Provincial People's Hospital

OTHER

collaborator

Chongqing Three Gorges Central Hospital

OTHER

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

lead

The Second Affiliated Hospital of Chongqing Medical University

OTHER